---

$22.88

+3.5750 ( +18.52% ) 3.4M

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-06-05	Sale	-400.00	Ring Christine
2024-06-03	Sale	-1596.00	Ring Christine
2024-05-20	Sale	-25000.00	Silva Paul M
2024-05-20	Sale	-25000.00	Kunkel Lori Anne
2024-05-20	Sale	-25000.00	GREGORY JULIA P